[Treatment of peptic ulcer using proglumide (Milid)].
20 patients with peptic gastric ulcer and 30 patients with peptic duodenal ulcer were treated with Milid (Proglumid). The following results were achieved: in 85% of the patients with peptic gastric ulcer and in 93% of the patients with duodenal ulcer the pain was relieved on the 4th day on the average. In 95-96% of the patients treated the dyspeptic complaints disappeared on the 2-3 day. The endoscopic examination performed on the 20th day revealed full epithelization of the ulcer in 30% of the patients with gastric ulcer and in 43.3% of the patients with duodenal ulcer. Following the treatment course the basic secretion and acid production fell statistically significantly in the patients with gastric ulcer while in the patients with duodenal ulcer the basic and stimulated secretion and acid production were suppressed. The drug Milid does not change the serum gastrin level but suppresses the gastrin secretion in the gastric juice. The Milid treatment leads to an increase of the quantity of the N-acetylneuraminic acid in the gastric juice which partly reflects the cytoprotective action of Milid. The drug can be used in the everyday practice for the treatment of peptic ulcer.
Brailski
Kh
Kh
Mendizova
A
A
Dimitrov
B
B
Vladimirov
B
B
Koparandova
O
O
D000328:Adult; D002908:Chronic Disease; D004341:Drug Evaluation; D004381:Duodenal Ulcer / Q000188:drug therapy*; D005260:Female; D005750:Gastric Juice / Q000032:analysis / Q000187:drug effects; D005753:Gastric Mucosa / Q000187:drug effects / Q000378:metabolism; D005773:Gastroscopy; D005973:Glutamine / Q000031:analogs & derivatives*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010418:Pentagastrin; D011377:Proglumide / Q000627:therapeutic use*; D013276:Stomach Ulcer / Q000188:drug therapy*
D005973:Glutamine; D010418:Pentagastrin; D011377:Proglumide
Lechenie na iazvenata bolest s proglumid (milid)]